K836E

Category 3/4 — Most DruggableUncertain significanceLumenal · predictedσ-1 candidateSource card

Lysine → Glutamic acid at position 836 · C-terminal ER-lumenal (calcium binding, calmodulin, chaperone) · WFS1 (Wolframin)

Interactive 3D Structure

Wild-type reference

Wild-type K836 — hydrophobic to W678

Fullscreen ↗

DynaMut2 mutant · K836E

Mutant E836 — energy-minimized; 1 new contact formed

Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

0 lost1 gained1 preserved

Interaction type	Wild-type partner	Mutant partner	Status
Polar contact	—	P838	Gained
Hydrophobic	W678	W678	Preserved

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG

-0.41kcal/mol

Destabilising — mild

AlphaMissense

0.989

likely pathogenic

AlphaFold pLDDT

model confidence

Schema

Cat 3/4

Category 3/4 — Most Druggable

Clinical Evidence

ClinVar classificationUncertain significance

Review statuscriteria provided, single submitter

Associated conditionsWolfram-like syndrome

Population frequency (gnomAD v4)Absent from gnomAD v4

cDNA changec.2506A>G

ClinVar accessionVCV004293166

Last evaluated2025/04/25 00:00

Not observed in ~730k individuals — consistent with a rare allele (ACMG PM2_supporting).

Full Variant Card

WFS1 Wolframin — K836E Variant Card

Molecular Atlas Pilot · RareResearch.AI · Generated by wolfram-variant-card skill

Lysine → Glutamic acid at position 836. C-terminal ER-lumenal (calcium binding. ClinVar Uncertain significance, AlphaMissense 0.989, DynaMut2 ΔΔG -0.41 kcal/mol (destabilising).

Identity

Field	Value
Variant	K836E (p.Lysine836Glutamic acid)
DNA change	c.2506A>G
Gene · Protein	WFS1 · Wolframin (890 aa)
UniProt	O76024 · WFS1_HUMAN
ClinVar accession	VCV004293166
Amino acid change	Lysine (K) → Glutamic acid (E)

Structural Context

Field	Value
AlphaFold model	AF-O76024-F1, v6
pLDDT at residue 836	81.75 — well-folded
Domain	C-terminal ER-lumenal (calcium binding, calmodulin, chaperone)
Position context	C-terminal lumenal domain · position 836 projects into the ER lumen
IDR flag	No — pLDDT above 50 threshold

UniProt features at this position:

(none catalogued)

Position 836 sits in the C-terminal lumenal domain (residues 653–869), wolframin's largest soluble region. This domain projects into the ER lumen and is implicated in calcium handling, ER stress sensing, and protein–protein interactions with ATF6 and Na+/K+ ATPase β1. The wild-type residue is positively charged (lysine — primary amine); the mutant is negatively charged (glutamate — carboxylate). The chemistry shift implies altered local packing, hydrogen-bonding, and/or electrostatics at this site.

Computational Predictions

AlphaMissense

Field	Value
am_pathogenicity	0.9889
am_class	likely pathogenic
Interpretation	Likely pathogenic (threshold 0.564)

DynaMut2

Field	Value
ΔΔG (kcal/mol)	-0.41 (Destabilising)
Job ID	178092089154
Result URL	https://biosig.lab.uq.edu.au/dynamut2/results_prediction/178092089154

Clinical Evidence

Field	Value
Classification	Uncertain significance
Review status	criteria provided, single submitter
Last evaluated	2025/04/25 00:00
Inheritance	Inheritance pattern not specified in ClinVar entry; WFS1 has both AD and AR presentations.
WFS1 variant landscape	K836E is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 catalogued in ClinVar)

Wolfram-like syndrome

Research Path Decision Tree

ΔΔG < 2  + binding site affected   →  CATEGORY 3 — docking experiments
ΔΔG 2–4                            →  CATEGORY 2 — pharmacological chaperones
ΔΔG > 4                            →  CATEGORY 1 — gene therapy
pLDDT < 50                         →  CATEGORY 5 — IDR, experimental only
Stable fold + functional site hit  →  CATEGORY 4 — site-specific docking

Final Schema Categorization

Category 3/4 — Most Druggable

<strong>Category 3/4 — Most Druggable</strong><br/><br/>|ΔΔG|=0.41 < 2 kcal/mol (fold intact) + AlphaMissense 0.989 confirms functional impact. Specific local contacts disrupted — priority for docking and pharmacological chaperone screening.

Why this card matters. Wolframin's fold survives this substitution (|ΔΔG|=0.41 kcal/mol). The pathogenic signal is real — AlphaMissense places it at 0.989. Protein still folds, but a specific local site is broken. Pharmacological chaperones and small-molecule binders are the rational therapeutic vector.

Files in this folder

AF-O76024-F1-model_v6.pdb — AlphaFold structure
K836E_molstar_viewer.html — interactive 3D viewer (auto-highlights position 836 with ball-and-stick + neighbors within 5Å)
K836E_variant_card.md — this card (source of truth)
K836E_variant_card.html — styled printable card
K836E_dynamut2_summary.html — clean offline DynaMut2 result card
dynamut2_result.json — structured result data
dynamut2_result_page.html — local snapshot of the Biosig result page (asset URLs absolutized)
K836E_wildtype_interactions.pse / K836E_mutant_interactions.pse — PyMOL sessions

Generated by wolfram-variant-card skill · RareResearch.AI Molecular Atlas Every assumption documented. Every score sourced.

Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the K836E PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download K836E PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.